Cencora, Inc. (NYSE:COR) Shares Sold by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC cut its stake in Cencora, Inc. (NYSE:COR) by 3.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,000 shares of the company’s stock after selling 1,000 shares during the period. Cencora accounts for approximately 2.4% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 18th largest holding. Sivik Global Healthcare LLC’s holdings in Cencora were worth $5,627,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. New Millennium Group LLC acquired a new position in shares of Cencora during the second quarter valued at about $26,000. TCTC Holdings LLC acquired a new stake in Cencora during the first quarter worth approximately $29,000. TFO Wealth Partners LLC bought a new position in Cencora in the 1st quarter valued at about $30,000. MFA Wealth Advisors LLC acquired a new stake in shares of Cencora during the 2nd quarter valued at $30,000. Finally, Concord Wealth Partners bought a new position in shares of Cencora during the third quarter worth about $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.80% of the stock is owned by insiders.

Cencora Trading Down 0.9 %

COR traded down $2.24 during trading on Thursday, reaching $247.73. The company had a trading volume of 47,972 shares, compared to its average volume of 1,401,661. Cencora, Inc. has a 12-month low of $191.11 and a 12-month high of $251.56. The firm’s 50-day simple moving average is $232.38 and its 200 day simple moving average is $231.00. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The company has a market cap of $48.82 billion, a price-to-earnings ratio of 33.28, a PEG ratio of 1.66 and a beta of 0.44.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be paid a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s dividend payout ratio (DPR) is presently 27.16%.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Barclays raised their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Leerink Partners dropped their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Evercore ISI upped their price target on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, JPMorgan Chase & Co. upped their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.